Medpace Holdings, Inc. $MEDP Shares Sold by PineStone Asset Management Inc.

PineStone Asset Management Inc. trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,200 shares of the company’s stock after selling 7,100 shares during the period. PineStone Asset Management Inc. owned approximately 0.10% of Medpace worth $15,013,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in MEDP. Hsbc Holdings PLC grew its position in Medpace by 157.5% during the first quarter. Hsbc Holdings PLC now owns 4,364 shares of the company’s stock valued at $1,296,000 after acquiring an additional 2,669 shares during the period. OMERS ADMINISTRATION Corp lifted its stake in shares of Medpace by 39.6% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 6,074 shares of the company’s stock valued at $1,851,000 after purchasing an additional 1,724 shares in the last quarter. State of Wyoming grew its holdings in shares of Medpace by 24.6% during the 1st quarter. State of Wyoming now owns 365 shares of the company’s stock worth $111,000 after purchasing an additional 72 shares during the period. Canada Pension Plan Investment Board increased its position in Medpace by 9.0% during the 1st quarter. Canada Pension Plan Investment Board now owns 47,400 shares of the company’s stock worth $14,442,000 after purchasing an additional 3,900 shares in the last quarter. Finally, Magnetar Financial LLC acquired a new stake in Medpace during the 1st quarter worth approximately $2,666,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MEDP. Cowen reiterated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Barclays upped their price target on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Robert W. Baird set a $613.00 price objective on Medpace in a research note on Friday, October 24th. Finally, BMO Capital Markets began coverage on Medpace in a research report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $490.82.

Insiders Place Their Bets

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This represents a 42.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the sale, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at $381,694,426.96. The trade was a 0.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 387,925 shares of company stock worth $233,386,647 in the last three months. 20.30% of the stock is owned by insiders.

Medpace Price Performance

Shares of MEDP stock opened at $567.56 on Friday. The company’s fifty day moving average price is $579.62 and its two-hundred day moving average price is $481.39. The firm has a market capitalization of $15.99 billion, a P/E ratio of 39.69, a P/E/G ratio of 2.14 and a beta of 1.43. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same period last year, the firm earned $3.01 earnings per share. The company’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.